The U.S. Court of Appeals for the Fifth Circuit on Friday blocked the online sale and mail delivery of the abortion drug mifepristone, temporarily restoring in-person screening requirements the FDA stripped away in 2023, a ruling that could reshape abortion access across all 50 states.

The decision, authored by Judge Stuart Kyle Duncan, sided with Louisiana in its lawsuit against the Food and Drug Administration. Duncan, appointed by President Donald Trump in 2018, found the state is "suffering irreparable harm" from the FDA's loosened dispensing rules, which allowed the drug to be prescribed via telehealth and shipped through the mail without a single in-person medical visit.

The ruling lands at the center of a legal and political fault line that has only widened since the Supreme Court overturned Roe v. Wade in 2022. Thirteen states, Louisiana among them, now prohibit elective abortion entirely. Yet the Biden-era FDA's decision to drop in-person requirements effectively opened a back channel, one that allowed mifepristone to reach women in those very states by mail, circumventing laws their legislatures passed.

Friday's order closes that channel. At least for now.

Louisiana's case: Medicaid costs, state sovereignty, and nearly 1,000 abortions a month

Louisiana Attorney General Liz Murrill, working alongside the Alliance Defending Freedom, filed suit against the FDA last fall, demanding reinstatement of the in-person dispensing requirement the agency had removed. Her complaint laid out a concrete financial harm: $92,000 in Medicaid costs to treat two women who needed emergency medical care in 2025 after complications from mail-order abortion pills.

That figure may sound modest. But the opinion made clear it represents only the visible tip. Duncan wrote that "nearly 1,000 women monthly, many of whom are on Medicaid, have mifepristone-induced abortions in Louisiana." Medicaid covers more than 40 percent of the state's population, including three in ten adults. The financial exposure for Louisiana taxpayers is not hypothetical.

The court found Louisiana had standing to sue the FDA on grounds of "causation and redressability." Duncan's opinion was blunt about the mechanism of harm: "By ending the in-person dispensing requirement, FDA opened the door for mifepristone to be remotely prescribed to Louisiana women."

And the opinion went further, framing the conflict not just as a regulatory dispute but as a direct collision between federal agency action and state law. As Duncan wrote:

"Every abortion facilitated by the FDA's action cancels Louisiana's ban on medical abortion and undermines its policy that 'every unborn child is human being from the moment of conception and is therefore, a legal person.'"

That language matters. It treats the FDA's loosened rules not as a neutral administrative adjustment but as a federal override of a state's democratically enacted abortion ban. For conservatives who fought for years to return abortion policy to the states, the Biden FDA's 2023 move looked like an end-run around the very principle the Dobbs decision was supposed to establish.

The FDA's regulatory shortcuts under scrutiny

Mifepristone was first approved for commercial use by the FDA more than two decades ago. For most of that time, it came with strict safety protocols, including in-person dispensing. The Biden administration removed those requirements in 2023, a move the Fifth Circuit's opinion said was made with the explicit intention of expanding access to abortion.

The Washington Free Beacon reported that the appeals court found the FDA's 2016 changes relaxing mifepristone restrictions were likely unlawful under administrative law. The court also concluded the agency's 2021 decision allowing remote prescribing and mailing of the drug was likely arbitrary and capricious, the legal standard for agency overreach.

Judge Jennifer Walker Elrod, writing in a related panel opinion, put it plainly. As the New York Post reported, she wrote: "In loosening mifepristone's safety restrictions, FDA failed to address several important concerns about whether the drug would be safe for the women who use it."

That is a damning assessment of an agency that claims scientific authority as its foundation. The FDA did not simply update a regulation. It dismantled safety guardrails for a drug used in nearly two-thirds of the more than 1.1 million abortions performed in the United States each year, and it did so without, in the court's judgment, adequately addressing the risks.

The ongoing tension between the Trump administration's DOJ and pro-life allies over abortion drug policy adds another layer of complexity to the legal landscape. Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary both promised during their confirmation hearings last year that the agency would conduct a new safety review of mifepristone following the removal of in-person dispensing protocols.

A federal district court had paused Murrill's lawsuit earlier this month to give the agency more time to complete that review. The Fifth Circuit's Friday ruling suggests the court was not willing to wait.

A unanimous panel and a nationwide reach

AP News reported that the ruling came from a unanimous three-judge panel. The decision requires mifepristone to be distributed only in person and at clinics, overruling FDA regulations that had permitted telehealth prescribing and mail distribution. The court itself acknowledged the scope: the stay would "as a practical matter, have a nationwide effect."

That nationwide reach is what makes the ruling so consequential. This is not a state-level restriction. It is a federal appeals court telling a federal agency that its regulatory choices were legally deficient, and temporarily reversing them across the country.

The Fox News report noted that judges criticized the FDA's handling of safety data and adverse-event reporting, siding with pro-life states that argued federal policy had undermined their abortion laws. Family Research Council President Tony Perkins called the ruling "great news for the unborn."

The Fifth Circuit has emerged as a key battleground in the broader legal fight over the boundaries between federal authority and state sovereignty. Friday's mifepristone ruling fits squarely within that pattern, a court willing to hold federal agencies accountable when they exceed their mandate.

Reaction from Louisiana and beyond

Attorney General Murrill did not mince words after the opinion circulated. She committed "to continuing to defend women and babies as this case continues," and cast the Biden-era policy in stark terms:

"The Biden abortion cartel facilitated the deaths of thousands of Louisiana babies (and millions in other states) through illegal mail-order abortion pills. Today, that nightmare is over."

Sen. Bill Cassidy, the Louisiana Republican described as a staunch anti-abortion advocate facing a tough primary this election cycle, celebrated the ruling on X Friday evening. Cassidy said women in Louisiana "have been coerced into taking these drugs shipped in from out of state without medical oversight," and called the ruling "a victory for mothers and babies in Louisiana."

Abortion-rights groups pushed back. Julia Kaye of the ACLU warned the decision would "affect patients' access to abortion and miscarriage care in every state in the nation." Planned Parenthood's Alexis McGill Johnson said the ruling "makes it clear that mifepristone's approval is very much still at risk, as is the FDA's independence."

That last claim deserves scrutiny. The FDA's "independence" is not a license to ignore administrative law. When an agency loosens safety restrictions on a powerful drug and a federal court finds it did so in an arbitrary and capricious manner, the proper response is not to invoke institutional prestige. It is to fix the process.

The National Review's legal analysis noted that the court did not revive challenges to the FDA's original 2000 approval of mifepristone or the 2019 approval of a generic version. The ruling targeted the specific regulatory loosening, not the drug's existence on the market. Legal commentator Ed Whelan described the decision as "a significant victory for the plaintiffs" on the 2016 and 2021 changes while clarifying that it did not alter the immediate status quo at the time of the earlier proceedings.

What comes next

The ruling sets the stage for a potential Supreme Court showdown, the second time the high court has been drawn into the mifepristone fight. The legal trajectory mirrors other high-profile court battles where federal judges have stepped in on politically charged questions, forcing higher courts to weigh in.

The Biden administration previously said it would appeal similar Fifth Circuit restrictions to the Supreme Court. Whether the current administration takes a different posture remains an open question, particularly given the broader pattern of federal appeals courts shaping administration policy through interim orders.

Meanwhile, the promised FDA safety review of mifepristone, the one Kennedy and Makary pledged during confirmation, hangs in the background. The district court gave the agency more time. The Fifth Circuit apparently decided the clock had run long enough.

For nearly 1,000 women a month in Louisiana alone, the immediate practical question is straightforward: a pill that arrived by mail last week now requires an in-person visit. For 13 states with abortion bans on the books, the ruling restores a measure of the sovereignty the Dobbs decision was supposed to guarantee.

When the FDA decided to let abortion pills travel by mail into states that had banned the procedure, it didn't just loosen a regulation. It told those states their laws didn't matter. The Fifth Circuit just told the FDA that its shortcuts do.